APO RESEARCH · REPORT
Bio Pharma Buffer
A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Product & engineering
Understand the product.
A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Most purification steps for downstream processing of biologics require buffers to equilibrate, condition, wash, elute, or concentrate the product. They are used in product isolation and purification steps to facilitate protein capture and polishing and also in the filtration process for the removal of viruses or depyrogenation. Aqueous solutions are also required for cleaning and disinfecting downstream processing equipment, such as chromatography matrices and membrane filtration systems. The main equipment involved in downstream processing with buffers includes mixers for buffer preparation, as well as equipment for purification, including packed-bed chromatography systems, fluidized beds, ultrafiltration and diafiltration membranes, microfiltration membranes, depth filtration cartridges, and virus-removal systems.
Selected research
Industry Research
Bio Pharma Buffer Industry Research Report 2026
Market perspective
A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Most purification steps for downstream processing of biologics require buffers to equilibrate, condition, wash, elute, or concentrate the product. They are used in product isolation and purification steps to facilitate protein capture and polishing and also in the filtration process for the removal of viruses or depyrogenation. Aqueous solutions are also required for cleaning and disinfecting downstream processing equipment, such as chromatography matrices and membrane filtration systems. The main equipment involved in downstream processing with buffers includes mixers for buffer preparation, as well as equipment for purification, including packed-bed chromatography systems, fluidized beds, ultrafiltration and diafiltration membranes, microfiltration membranes, depth filtration cartridges, and virus-removal systems.
The key players are Avantor, Alfa Aesar (Thermo Fisher), Merck, Lonza, Bio-Rad, BD, GE, Healthcare, Promega Corporation, Hamilton Company, XZL BIO-TECHNOLOGY, SRL and so on. According to the revenue of these companies, we can know that the Bio Pharma Buffer industry is relative concentrated. Because the top 6 companies have more than 70% market share.
Read the full market overview
Report Scope
This report quantifies the global Bio Pharma Buffer market in terms of revenue (US$ million) and, where applicable, sales volume (K Liter), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Liter) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bio Pharma Buffer Market by Company
Avantor
Alfa Aesar (Thermo Fisher)
Merck
Lonza
Bio-Rad
BD
GE Healthcare
Promega Corporation
Hamilton Company
XZL BIO-TECHNOLOGY
SRL
Bio Pharma Buffer Segment by Type
Phosphates Type
Acetates Type
TRIS Type
Others
Bio Pharma Buffer Segment by Application
Research Institution
Pharmaceutical Industry
Others
Bio Pharma Buffer Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bio Pharma Buffer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bio Pharma Buffer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bio Pharma Buffer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bio Pharma Buffer manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bio Pharma Buffer by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bio Pharma Buffer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Phosphates Type
- Acetates Type
- TRIS Type
- Others
Applications
- Research Institution
- Pharmaceutical Industry
- Others
Companies covered
- Avantor
- Alfa Aesar (Thermo Fisher)
- Merck
- Lonza
- Bio-Rad
- BD
- GE Healthcare
- Promega Corporation
- Hamilton Company
- XZL BIO-TECHNOLOGY
- SRL
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Bio Pharma Buffer Market Size (2021-2032)
- 2.2.2 Global Bio Pharma Buffer Sales (2021-2032)
- 2.2.3 Global Bio Pharma Buffer Market Average Price (2021-2032)
- 2.3 Bio Pharma Buffer by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Phosphates Type
- 2.3.3 Acetates Type
- 2.3.4 TRIS Type
- 2.3.5 Others
- 2.4 Bio Pharma Buffer by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Research Institution
- 2.4.3 Pharmaceutical Industry
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Bio Pharma Buffer Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Bio Pharma Buffer Sales (K Liter) of Manufacturers (2021-2026)
- 3.3 Global Bio Pharma Buffer Revenue of Manufacturers (2021-2026)
- 3.4 Global Bio Pharma Buffer Average Price by Manufacturers (2021-2026)
- 3.5 Global Bio Pharma Buffer Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Bio Pharma Buffer, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Bio Pharma Buffer, Product Type & Application
- 3.8 Global Manufacturers of Bio Pharma Buffer, Established Date
- 3.9 Global Bio Pharma Buffer Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Avantor
- 4.1.1 Avantor Company Information
- 4.1.2 Avantor Business Overview
- 4.1.3 Avantor Bio Pharma Buffer Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Avantor Bio Pharma Buffer Product Portfolio
- 4.1.5 Avantor Recent Developments
- 4.2 Alfa Aesar (Thermo Fisher)
- 4.2.1 Alfa Aesar (Thermo Fisher) Company Information
- 4.2.2 Alfa Aesar (Thermo Fisher) Business Overview
- 4.2.3 Alfa Aesar (Thermo Fisher) Bio Pharma Buffer Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Alfa Aesar (Thermo Fisher) Bio Pharma Buffer Product Portfolio
- 4.2.5 Alfa Aesar (Thermo Fisher) Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Bio Pharma Buffer Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Bio Pharma Buffer Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Lonza
- 4.4.1 Lonza Company Information
- 4.4.2 Lonza Business Overview
- 4.4.3 Lonza Bio Pharma Buffer Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Lonza Bio Pharma Buffer Product Portfolio
- 4.4.5 Lonza Recent Developments
- 4.5 Bio-Rad
- 4.5.1 Bio-Rad Company Information
- 4.5.2 Bio-Rad Business Overview
- 4.5.3 Bio-Rad Bio Pharma Buffer Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bio-Rad Bio Pharma Buffer Product Portfolio
- 4.5.5 Bio-Rad Recent Developments
- 4.6 BD
- 4.6.1 BD Company Information
- 4.6.2 BD Business Overview
- 4.6.3 BD Bio Pharma Buffer Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 BD Bio Pharma Buffer Product Portfolio
- 4.6.5 BD Recent Developments
- 4.7 GE Healthcare
- 4.7.1 GE Healthcare Company Information
- 4.7.2 GE Healthcare Business Overview
- 4.7.3 GE Healthcare Bio Pharma Buffer Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GE Healthcare Bio Pharma Buffer Product Portfolio
- 4.7.5 GE Healthcare Recent Developments
- 4.8 Promega Corporation
- 4.8.1 Promega Corporation Company Information
- 4.8.2 Promega Corporation Business Overview
- 4.8.3 Promega Corporation Bio Pharma Buffer Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Promega Corporation Bio Pharma Buffer Product Portfolio
- 4.8.5 Promega Corporation Recent Developments
- 4.9 Hamilton Company
- 4.9.1 Hamilton Company Company Information
- 4.9.2 Hamilton Company Business Overview
- 4.9.3 Hamilton Company Bio Pharma Buffer Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Hamilton Company Bio Pharma Buffer Product Portfolio
- 4.9.5 Hamilton Company Recent Developments
- 4.10 XZL BIO-TECHNOLOGY
- 4.10.1 XZL BIO-TECHNOLOGY Company Information
- 4.10.2 XZL BIO-TECHNOLOGY Business Overview
- 4.10.3 XZL BIO-TECHNOLOGY Bio Pharma Buffer Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 XZL BIO-TECHNOLOGY Bio Pharma Buffer Product Portfolio
- 4.10.5 XZL BIO-TECHNOLOGY Recent Developments
- 4.11 SRL
- 4.11.1 SRL Company Information
- 4.11.2 SRL Business Overview
- 4.11.3 SRL Bio Pharma Buffer Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 SRL Bio Pharma Buffer Product Portfolio
- 4.11.5 SRL Recent Developments
5 Global Bio Pharma Buffer Market Scenario by Region
- 5.1 Global Bio Pharma Buffer Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Bio Pharma Buffer Sales by Region: 2021-2032
- 5.2.1 Global Bio Pharma Buffer Sales by Region: 2021-2026
- 5.2.2 Global Bio Pharma Buffer Sales by Region: 2027-2032
- 5.3 Global Bio Pharma Buffer Revenue by Region: 2021-2032
- 5.3.1 Global Bio Pharma Buffer Revenue by Region: 2021-2026
- 5.3.2 Global Bio Pharma Buffer Revenue by Region: 2027-2032
- 5.4 North America Bio Pharma Buffer Market Facts & Figures by Country
- 5.4.1 North America Bio Pharma Buffer Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Bio Pharma Buffer Sales by Country (2021-2032)
- 5.4.3 North America Bio Pharma Buffer Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Bio Pharma Buffer Market Facts & Figures by Country
- 5.5.1 Europe Bio Pharma Buffer Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Bio Pharma Buffer Sales by Country (2021-2032)
- 5.5.3 Europe Bio Pharma Buffer Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Bio Pharma Buffer Market Facts & Figures by Country
- 5.6.1 Asia Pacific Bio Pharma Buffer Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Bio Pharma Buffer Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Bio Pharma Buffer Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Bio Pharma Buffer Market Facts & Figures by Country
- 5.7.1 South America Bio Pharma Buffer Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Bio Pharma Buffer Sales by Country (2021-2032)
- 5.7.3 South America Bio Pharma Buffer Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Bio Pharma Buffer Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Bio Pharma Buffer Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Bio Pharma Buffer Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Bio Pharma Buffer Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Bio Pharma Buffer Sales by Type (2021-2032)
- 6.1.1 Global Bio Pharma Buffer Sales by Type (2021-2032) & (K Liter)
- 6.1.2 Global Bio Pharma Buffer Sales Market Share by Type (2021-2032)
- 6.2 Global Bio Pharma Buffer Revenue by Type (2021-2032)
- 6.2.1 Global Bio Pharma Buffer Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Bio Pharma Buffer Revenue Market Share by Type (2021-2032)
- 6.3 Global Bio Pharma Buffer Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Bio Pharma Buffer Sales by Application (2021-2032)
- 7.1.1 Global Bio Pharma Buffer Sales by Application (2021-2032) & (K Liter)
- 7.1.2 Global Bio Pharma Buffer Sales Market Share by Application (2021-2032)
- 7.2 Global Bio Pharma Buffer Revenue by Application (2021-2032)
- 7.2.1 Global Bio Pharma Buffer Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Bio Pharma Buffer Revenue Market Share by Application (2021-2032)
- 7.3 Global Bio Pharma Buffer Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Bio Pharma Buffer Value Chain Analysis
- 8.1.1 Bio Pharma Buffer Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Bio Pharma Buffer Production Mode & Process
- 8.2 Bio Pharma Buffer Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Bio Pharma Buffer Distributors
- 8.2.3 Bio Pharma Buffer Customers
9 Global Bio Pharma Buffer Analyzing Market Dynamics
- 9.1 Bio Pharma Buffer Industry Trends
- 9.2 Bio Pharma Buffer Industry Drivers
- 9.3 Bio Pharma Buffer Industry Opportunities and Challenges
- 9.4 Bio Pharma Buffer Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst